0
Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

Gemcitabine Åõ¿©È¯ÀÚÀÇ Ç÷°üÅë ½ÇÅÂ¿Í ÀÓ»ó¿äÀο¡ µû¸¥ Ç÷°üÅë Â÷ÀÌ

A Study on Vascular Pain Due to Gemcitabine and According to Clinical Factors

Á¾¾ç°£È£¿¬±¸ 2013³â 13±Ç 4È£ p.210 ~ 221
KMID : 1035120130130040210
¼º¼Ò·É ( Seong So-Ryoung ) - ¼­¿ï¾Æ»êº´¿ø °£È£ºÎ

À̳²ÁÖ ( Lee Nam-Ju ) - ¼­¿ï¾Æ»êº´¿ø °£È£ºÎ
À̹ÌÁø ( Lee Mi-Jin ) - ¼­¿ï¾Æ»êº´¿ø °£È£ºÎ
ÀåÇö¾Æ ( Jang Hyun-Ah ) - ¼­¿ï¾Æ»êº´¿ø °£È£ºÎ
¼Û¹ÎÁÖ ( Song Min-Ju ) - ¼­¿ï¾Æ»êº´¿ø °£È£ºÎ
¹Ú¼¼Á¤ ( Park Se-Jung ) - ¼­¿ï¾Æ»êº´¿ø °£È£ºÎ
±èÁöÀ± ( Kim Jee-Yoon ) - ¼­¿ï¾Æ»êº´¿ø °£È£ºÎ
·ù¹é·Ä ( Ryoo Baek-Yeol ) - ¼­¿ï¾Æ»êº´¿ø Á¾¾ç³»°ú

Abstract

Purpose: This study was performed to examine vascular pain due to gemcitabine and according to clinical factors.

Methods: The survey was performed with 525 cancer patients visiting chemotherapy infusion room in one general hospital. The data were collected via self-reported questionnaire, researchers observation, and reviewing medical records. Data were analyzed descriptive statistics, ttest, Kruskal-Wallis test, Tukey test using ranks, Jonckheere-Terpstra test, and Spearman correlation analysis were used.

Results: The mean scores of the intensity and onset time of vascular pain were 3.06¡¾2.16 and 8.13¡¾13.13 min, and each other were negative correlaton. Degree of intensity of vascular pain had a significant difference on gender (p=.003), age (p=.004), weight (p=.019), Body mass index (BMI) (p=.005), Body surface area (BSA) (p=.030), infusion time (p<.001), dose (p=.027), dose per minute (p<.001), the number of administered gemcitabine (p=.005), combination chemotherapeutic drug (p=.013) and tumor type (p=.002). Degree of onset time of vascular pain had a significant difference on infusion time (p=.044), combination chemotherapy (p=.001) and injection site (p=.001).

Conclusion: Patients administrated gemcitabine were experiencing various vascular pain, and vascular pain had a difference on clinical factors. Therefore, oncology nurses should be considered significant clinical factors to implement effective interventions to patients administered gemcitabine.
KeyWords
Áª½ÃŸºó, Ç÷°üÅë, ¾Ï ȯÀÚ
Gemcitabine, Vascular, Pain, Neoplasms
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
ÇмúÁøÈïÀç´Ü(KCI) KoreaMed